Regeneron PharmaceuticalsMIL:1REGN +2.45%28 OCF Margin % is 29.92% as of Mar. 2026, which is 14% below its 10-year median of 34.87. GuruFocus rates MIL:1REGN with a GF Score™ of 28/100 and a GF Value™ of €786.02 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 959 Biotechnology companies, Regeneron Pharmaceuticals ranks better than 90.41% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1REGN vs ALNY, RVMD, ONC: OCF Margin % Comparison
For the Biotechnology subindustry, Regeneron Pharmaceuticals's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regeneron Pharmaceuticals (MIL:1REGN) has a OCF Margin % of 29.92% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Regeneron Pharmaceuticals and its competitors. This is 14% below median its historical median of 34.87. Over the past decade, Regeneron Pharmaceuticals' OCF Margin % has ranged from 22.26 to 44.06. According to the industry distribution chart, Regeneron Pharmaceuticals ranks #92 out of 959 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Regeneron Pharmaceuticals' OCF Margin % too high?
Regeneron Pharmaceuticals' current OCF Margin % of 29.92% is 14% below median its 10-year median of 34.87. Over the past 10 years, this metric has ranged from a low of 22.26 to a high of 44.06. Based on the distribution chart, Regeneron Pharmaceuticals ranks #92 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Regeneron Pharmaceuticals has a GF Score™ of 28/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' OCF Margin % compare to ALNY and RVMD?
According to the Biotechnology industry distribution chart, Regeneron Pharmaceuticals ranks #92 out of 959 companies for OCF Margin %. This places Regeneron Pharmaceuticals in the top 10% of its industry — outperforming the majority of peers. Historically, Regeneron Pharmaceuticals' own OCF Margin % has ranged from 22.26 to 44.06 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current OCF Margin % is 29.92%, which is 14% below median its own 10-year median of 34.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (MIL:1REGN) is currently considered Significantly Undervalued. The stock's GF Value™ is €786.02, compared to a current price of €540.20 — trading 31.3% below its estimated fair value. The current OCF Margin % is 29.92%, which is 14% below median its 10-year median of 34.87. Regeneron Pharmaceuticals' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Regeneron Pharmaceuticals (MIL:1REGN), the current OCF Margin % is 29.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regeneron Pharmaceuticals (MIL:1REGN) Overvalued in 2026?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued.
The current stock price of €540.20 is trading 31.3% below its estimated GF Value™ of €786.02.
GuruFocus considers Regeneron Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for MIL:1REGN:
OCF Margin %: 29.92% (14% below median its 10-year median of 34.87)
GF Value™: €786.02 vs. price of €540.20 (31.3% below fair value)
No single metric tells the full story. See the MIL:1REGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
28GF Score
Get the complete analysis for MIL:1REGN
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1REGN has been successfully added to your 
